Marathon Pharmaceuticals, LLC today announced Dave Bradshaw has joined the company as executive director of manufacturing. In this role, Bradshaw will oversee the manufacturing and supply operations for Marathon Pharmaceuticals’ rapidly growing portfolio of treatments.
Bradshaw, 52, has over 30 years of experience in pharmaceutical manufacturing. He previously served as senior director of manufacturing for Recordati Rare Diseases, Lundbeck, Inc. and Ovation Pharmaceuticals. Bradshaw also held leadership roles at Biomira, Chiron and Pathogenesis.
As part of Marathon’s executive team, Bradshaw is responsible for ensuring that the drug supply chain, from raw material acquisition to final product delivery, meets Marathon’s high standards for timeliness, quality and regulatory compliance.
“Excellence in manufacturing is a critical part of Marathon’s commitment to making medications available for the patients who need them,” Said Dr. Michael Rice, Marathon Pharmaceuticals vice president of technical operations. “Dave’s deep experience in complex pharmaceutical manufacturing will be an important asset as Marathon continues to commercialize new treatments.”
Bradshaw holds a degree in chemistry from Fairleigh Dickinson University. He will be based out of New Jersey.
Earlier this month Marahton added a new head of corporate development Babar Ghias, vice president of corporate development.
Ghias, 35, most recently served as Director for Credit Suisse’s Mergers & Acquisitions Group in New York, where he led completion of more than $80 billion in transactions for small and large-cap client companies, primarily in the global healthcare sector.
As part of Marathon’s executive team, Ghias is responsible for identifying and evaluating business development opportunities, deal structuring, financial strategy and managing Marathon’s capital structure. In addition, he will proactively create beneficial relationships with private equity players, pharmaceutical companies, and investment bankers.
“Babar’s expertise in creatively executing deals will be very valuable to Marathon as it builds its portfolio of treatments for rare diseases. His work is integral to fulfilling our mission to deliver novel therapies to patients who currently have none,” said Jeffrey Aronin, Marathon Pharmaceuticals’ CEO.
Marathon also announced that they were opening a bioscience center in Chicago for their research, clinical and regulatory staff. Providing them with direct access to the new technology ventures located at MATTER, the University Tech Park at IIT and EntrepriseWorks Chicago’s HTI facility.